-

$undefined

N/A

(N/A)

MorphoSys AG NASDAQ:MOR MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.

Location: Semmelweisstr. 7, Bayern, 82152, Germany | Website: https://www.morphosys.de/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

116.15%

Insider Ownership

0.00%

Institutional Own.

7.44%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Monjuvi (Tafasitamab) (CD19) Details B-cell malignancies, Diffuse large B cell lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tremfya (guselkumab) (IL-23) Details Psoriatic arthritis, Plaque psoriasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tafasitamab (CD19) Details Cancer, B-cell malignancies, B-cell lymphoma, Diffuse large B cell lymphoma Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelabresib (CPI-0610) + ruxolitinib Details Myelofibrosis, Cancer, Bone marrow cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gantenerumab Details Alzheimer's disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tulmimetostat /CPI-0209 (EZH2 inhibitor) Details Cancer, Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.